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Background/aim: Isolated methylmalonic acidemia (MMA) is caused by complete or partial deficiency of the enzyme methylmalonylCoA mutase (mut0 or mut– enzymatic subtype), a defect of its cofactor adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency
of the enzyme methylmalonyl-CoA epimerase. While onset of the disease ranges from the neonatal period to adulthood, most cases
present with lethargy, vomiting and ketoacidosis in the early infancy. Major secondary complications are; growth failure, developmental
delay, interstitial nephritis with progressive renal failure, basal ganglia injury and cardiomyopathy. We aimed to demonstrate clinical and
molecular findings based on long-term follow up in our patient cohort.
Materials and methods: The study includes 37 Turkish patients with isolated MMA who were followed up for long term complications
1 to 14 years. All patients were followed up regularly with clinical, biochemical and dietary monitoring to determine long term
complications. Next Generation Sequencing technique was used for mutation screening in five disease-causing genes including; MUT,
MMAA, MMAB, MMADHC, MCEE genes. Mutation screening identified 30 different types of mutations.
Results: While 28 of these mutations were previously reported, one novel MMAA mutation p.H382Pfs*24 (c.1145delA) and one novel
MUT mutation IVS3+1G>T(c.752+1G>T) has been reported. The most common clinical complications were growth retardation, renal
involvement, mental motor retardation and developmental delay. Furthermore, one of our patients developed cardiomyopathy, another
one died because of hepatic failure and one presented with lactic acidosis after linezolid exposure.
Conclusion: We have detected two novel mutations, including one splice-site mutation in the MUT gene and one frame shift mutation
in the MMAA gene in 37 Turkish patients. We confirm the genotype-phenotype correlation in the study population according to the
long-term complications.
Key words: Methylmalonic acidemia, novel mutations, complications, outcome

1. Introduction
Isolated methylmalonic acidemia (MMA, OMIM
251000) consists of a group of genetically heterogeneous
inborn errors of metabolism characterized by abnormal
accumulation of methylmalonyl-CoA and methylmalonic
acid (MA) in body fluids without hyperhomocysteinemia
[1]. MMA is an autosomal recessive error of organic
acid metabolism caused by the impaired isomerization
of L-methylmalonyl-CoA to succinylCoA during the
oxidation of propionate towards the Krebs cycle [2].
Isolated MMA is caused by complete or partial deficiency
of the mitochondrial enzyme L-methylmalonylCoA
mutase (MCM, EC 5.4.99.2) (mut 0 enzymatic subtype
or mut– enzymatic subtype, respectively), a defect in the

handling of its cofactor, AdoCbl (cblA (OMIM607481),
cblB (OMIM607568), or cblD2 variant-MMA (OMIM
606169), or deficiency of the enzyme methylmalonylCoA epimerase (MCE) [3]. The five genes known to cause
isolated MMA include MUT, MMAA, MMAB, MMADHC,
MCEE genes, which are responsible for the MCM, cblA,
cblB, and cblD2 variant, MCE deficiency, respectively [4–
7].
The disease typically presents in the first weeks or
months of life and is clinically characterized by recurrent
vomiting, poor feeding, failure to thrive, respiratory
distress, and neurological deficit from progressive
alteration of consciousness to deep coma and death [8].
Ketoacidosis, hypo/hyperglycemia, hyperammonemia,
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anemia/pancytopenia are the main laboratory findings
[8]. Lethal ketoacidosis attacks can follow intercurrent
illnesses and it can even mimic diabetic ketoacidosis
[9,10]. The mut 0 type, is characterized by significantly low
apoenzyme activity, which is not more than 0.1 %, often
presents with metabolic acidosis within the first week after
birth, frequently resulting in death in early childhood.
The mut 0 type usually presents with repeated attacks of
ketoacidosis which are triggered by infection and high
protein intake during the weaning period after the age of
1 year [11].
Methylmalonyl-CoA
accumulates
in
the
mitochondrial matrix as a result of MCM deficiency, thus
it is subsequently hydrolyzed to CoA and MA, resulting in
elevated blood and urine levels of MA [12]. The excessive
accumulation of methylmalonic acid and its CoA esters
may inhibit mitochondrial enzymes [13,14]. Even with
the dietary treatment, affected patients experience various
life-threatening metabolic crises, and most patients have
problems with growth and motor skills [15]. Although
there is a significant improvement in the therapeutic
opportunities over the last 20-year-period, the overall
outcome of patients with MMA remained almost stable
as the number of long-term complications such as failure
to thrive, developmental delay, neurologic disorders by
degeneration of the basal ganglia, progressive renal failure,
and cardiomyopathy has been increasing [16–19]. It is
predicted that some mediators like 2-methylcitrate, MA,
and other propionate derived mediators inhibit some of
the mitochondrial enzymes. 2-methylcitrate inhibits the
tricarboxylic acid (TCA) cycle enzymes citrate synthase,
aconitase, and isocitrate dehydrogenase.MA inhibits
pyruvate carboxylase and propionyl-CoA inhibits CoA
dependent enzymes, such as pyruvate dehydrogenase,
succinyl-CoA synthetase, and ATP citrate lyase [20].
Furthermore, some studies provided data about the
increased levels of lactate particularly in globi pallidi,
which indicates a secondary respiratory chain deficiency
[14,21].
In this study, we report the clinical features, long term
complications, and genetic defects in the MUT, MMAA,
and MMAB genes of 37 Turkish patients affected with
isolated MMA.
2. Materials and methods
This is a retrospective cohort study between June 2013 and
June 2016. Patient data extracted from previous medical
records. Written informed consent obtained from all
participants during their clinical visits and conducted
according to the Declaration of Helsinki.
2.1. Patients
The study includes 37 Turkish patients with isolated
MMA, who were diagnosed and have been followed up at

the Department of Pediatric Metabolism and Nutrition,
Çukurova University, Adana, Turkey between June 2013
and June 2016. Unfortunately, none of the patients were
diagnosed through neonatal screening, all patients were
diagnosed by urine organic acid analysis and the blood
carnitine acylcarnitine profile after presenting clinical
symptoms and/or developing complications. Enzyme
activity assay cannot be performed. Metabolic treatments,
including protein restriction (with administration of
isoleucine-, methionine-, threonine-, and valine-free
special formulas), oral carnitine supplementation,
intermittent eradication of gut flora by metronidazole or
neomycin, and cobalamin (either oral or intramuscular
administration) were given to all patients. They were all
followed up for long-term complications 1 to 14 years.
Emergency treatment was performed during acute
metabolic crises.
2.2. Chronic management and follow-up
Neurological examination with detailed history of
developmental milestones was a routine part of evaluation
in every visit to the metabolic clinic. All patients were
screened with laboratory markers of renal function
including urinary electrolytes and protein loss, blood urea
nitrogen (BUN,) and creatinine. Creatinine clearances were
calculated according to the Schwartz formula annually in
all patients to assess the glomerular filtration rates [22].
A glomerular filtration rate under 80ml/min/1.73 m2
was defined as renal failure. All patients were routinely
screened with echocardiography and electrocardiography
(ECG) yearly for cardiac complications.
2.3. Mutation analysis
Mutation analysis performed for all participants and results
were obtained from medical records, retrospectively.
Genomic DNA was isolated from 2 mL EDTA blood
samples obtained by venipuncture on antecubital vein.
Next generation sequencing (NGS) technique was used
for mutation screening in five disease-causing genes by
Illumina-Miseq (Illumina, San Diego, CA, USA) by using
in-house designed primers. Mutation analysis was done
directly to the gene in question in case there is a preliminary
clinical diagnosis. In cases without a differential diagnosis
within these five, all five genes were sequenced. The
integrative genomics viewer (IGV) software of Broad
Institute was used for analysis and comparison with
reference sequence. All variations were evaluated by
and checked in HGMD-Public version, ClinVar, specific
databases, 1000 genome database, EXAC and 2000 exome
data of Intergen Genetics Center, Google search for the
mutations and all mutations, both previously published
and unpublished ones were evaluated with ACMG
criterias, DANN, GERP, dbNSFP. FATHMM, FATHMMMKL, LRT, MetaLR, MetaSVM, Mutation Assessor,
Mutation Taster, SIFT, PROVEAN, and Polyphen2. For
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the splicing defects, we also used Human Splicing Finder
program for the prediction. Family screening studies were
done for the variants predicted as variant of uncertain
significance (VUS) for segregation studies.
3. Results
A total of 37 patients representing 36 Turkish families
(patients 4 and 5 are siblings) are included in this study.
Nineteen of 37 (51.4%) patients were male and 18 of 37 (48.6)
were female. The clinical features and complementation
groups of all patients are summarized in Table 1. Nineteen
of 37 patients (51%) presented in the neonatal period
(between the ages of 1 and 30 days), while the remaining
18 patients presented in the later infancy period (between
the ages of 3 and 24 months). Consanguinity was noted
in 33 out of 36 families (92%). The interval from the age
of onset to the age at diagnosis was between 2 days and
7 months, except for patient 14, who had an older sibling
(patient 13) known to have MMA and was diagnosed at
the age of 4 days. Three patients died during subsequent
metabolic crises and one of them died because of severe
hepatic coma. 32 patients are alive (ages range from
12 months to 14 years), and they were all followed up
regularly in the interim period. The most common clinical
and biochemical features described were acute episodes
of vomiting, poor feeding, failure to thrive, lethargy,
hypotonia, and neurological abnormalities with metabolic
acidosis, hyperammonemia and methylmalonic aciduria.
Other frequently reported features are neurological
complications such as developmental delay and mental
and motor retardation and renal involvement. 12 out of
37 patients (32%) have some degree of renal involvement.
Patient 3 had early-onset and rapidly progressive renal
complications, specifically renal tubular acidosis (RTA)
type 4 and chronic kidney disease (CKD) stage 3, despite
good metabolic control. Patient 10 developed dilated
cardiomyopathy with decreased left ventricular ejection
fraction (LVEF) of 31% (normal>55%) during a severe
metabolic episode at the age of 14 months. When she
was 19 months old, she had a severe pneumonia, and she
was transferred to the intensive care unit on day 10 of
the hospital admission due to the respiratory failure. The
antibiotic therapy was advanced to vancomycin. Because
of decreased renal function (estimated renal clearance was
under 30 mL/min), intravenous linezolid (600 mg q/12 h)
was given as an alternative treatment to vancomycin. After
the administration of the third dose of linezolid, her blood
lactate levels had increased to 10.0 mmol/L. As linezolid
was suspected as a potential cause of the lactic acidosis,
the agent was stopped. The patient required mechanical
ventilation because of respiratory failure and continuous
renal replacement therapy was started to normalize her
blood pH and clear linezolid from her plasma.

1222

Eighteen out of thirty-seven patients (49%) had
variable neurologic complications, including mental
retardation, developmental delay, seizures and metabolic
stroke due to the basal ganglia infarction. Growth failure
and failure to thrive were identified in 21 out of 37 cases
(57%). Overall, 26 out of 37 cases (70%), who are older
than 1 year of age, were affected with one of the long-term
complications related to isolated MMA.
Thirty-seven isolated MMA patients were classified
in 3 complentation groups: mut, cblA, and cblB. 22 were
mut (60%), 12 cblA (32%), and 3 cblB (8%) forms (Table
2). Mutation screening identified 30 mutant alleles in all
patients diagnosed as isolated MMA. Thirty-five patients
were homozygous, and two patients had compound
heterozygous mutations. Ninety-four percent (33/35)
of the homozygous patients had documented parental
consanguinity, only two were nonconsanguineous. Clinical
phenotypes were correlated with the genotypes identified.
Among identified mutant alleles, 9 different MMAA
alleles, 3 different MMAB alleles, and 18 different MUT
alleles were described. While 28 of these mutant alleles
were previously reported, one novel MMAA mutation
p.H382Pfs*24 (c.1145delA) and one novel MUT
mutation IVS3+1G>T (c.752+1G>T) has been reported.
p.H382Pfs*24 (c.1145delA) is a frame shift mutation
in exon 7, which is detected in both alleles of patient
35. Patient 31, who does not have consanguinity, had
IVS3+1G>T (c.752+1G>T), which is located in splice
site sequence along with a heterozygous mutated allele
p.R108H (c.323G>A). Novel MUT and MMAA mutations
have not been reported in the locus specific databases
including, the Human Gene Mutation Database, ClinVar,
specific databases, 1000 genome database, EXAC and 2000
exome data of Intergen Genetics Center.
Two previously recognized polymorphisms in MUT
gene; p.R532H, and p.I671V were reported in patient 2 and
3, respectively. Both patients presented in the first year of life
with vomiting, rapid breathing, and restlessness, and was
found to have severe metabolic acidosis with an increased
anion gap. Tandem mass spectrometry analysis showed
significant elevation of propionylcarnitine, which may be
indicative of organic acidemia. While plasma amino acid
levels were found to be within normal limits, urine organic
acid analysis indicated marked excretion of methylmalonic
acid and methylcitric acid, which confirmed the diagnosis
of MMA. They both presented with typical MMA features.
Under protein-restricted dietary treatment they both had
various subsequent metabolic crisis. While patient 2 who
had homozygous p.R532H polymorphism developed
growth retardation and mental-motor retardation during
the follow-up, patient 3 who had p.I671V in a homozygous
state presented with severe renal failure and combined
liver-renal transplantation was performed at the age of 16.
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Table 1. Clinical characterization of the isolated MMA patients.
Patient
Consan- Age of
Sex
no
guinity onset

Outcome/
Long-term complications
Current age (years)

Zygosity

1

M

Yes

6m

Alive/6

DD, GR

H

MMAA gene
p.E773* (c.1117G>T)

2

M

Yes

1m

Alive/8

GR, MMR

H

MUT gene
p.R532H (c.1595G>A)

3

M

No

10 m

Alive/15

RI, Liver-renal
transplantation, GR

H

MUT gene
p.I671V (c.2011A>G)

4

F

Yes

8m

Alive/11

DD, MMR, GR

H

MUT gene
p.T387I (c.1160C>T)

5

M

Yes

10 m

Alive/6

NA

H

MUT gene
p.T387I (c.1160C>T)

6

M

No

12 m

Alive/5

RI, GR

CH

MUT gene c.2055_2056insCTC /
p.R727* (c.2179C>T)

7

F

Yes

6m

Died

MMR, contractures, GR

H

MUT gene p.M1T (c.2T>C)

8

M

Yes

3d

Alive/6

RI, GR

H

MUT gene
p.G454E (c.1361G>A)

9

F

Yes

10 m

Alive/6

DD,RI

H

MMAA gene
p.H382Pfs*24 (c.1145delA)

10

F

Yes

3d

Alive/5

RI,CMP, GR LA

H

MUT gene
p.G454E (c.1361G>A)

11

M

Yes

6m

Alive/12

DD, MMR, RI, GR

H

MMAB gene
p.R191W (c.571C>T)

12

F

Yes

20 d

Died

HF, GR

H

MUT gene p.N219Y (c.655A>T)

13

F

Yes

24 m

Alive/8

MMR, RI

H

MMAA gene p.G278D (c.833G>A)

14

F

No

25 d

Died

MMR contractures, GR, RI H

MUT gene p.K223R (c.668A>G)

15

M

Yes

15 m

Died

MMR, GR, RI

H

MUT gene p.R694W (c.2080C>T)

16

M

Yes

3d

Alive/3

DD

H

MUT gene p.N219Y (c.655A>T)

17

F

Yes

18 d

Alive/6

MR

H

MMAA gene p.R359Q (c.1076G>A)

18

F

Yes

13 d

Alive/8

RI, DD, MR GR

H

MUT gene p.A141Rfs*39 (c.421delG)

19

F

Yes

3d

Alive/1

DD

H

MMAA genep.R196* (c.586C>T)

20

F

Yes

22 d

Alive/11

MMR, GR

H

MMAB gene p.E193K (c.577G>A)

21

F

Yes

5d

Alive/10

GR

H

MMAA gene c.1075C>T (p.R359*)

22

M

Yes

20 d

Alive/1

NA

H

MMAA gene c.658G>A (p.V220M)

23

M

Yes

3d

Alive/7

DD, RI, GR

H

MUT gene
p.347delL(c.1038_1040delTCT)

24

F

Yes

2d

Alive/5

NA

H

MUT gene p.K121* (c.360_361insT)

25

M

Yes

3d

Alive/2

NA

H

MMAA gene p.R330*
(c.988C>T )

26

F

Yes

4m

Alive/2

DD

H

MUT gene p.K121* (c.360_361insT)

27

M

Yes

6m

Died

MMR Dystonia
Epilepsy, RI, GR

H

MUT gene p.K121* (c.360_361insT)

28

F

Yes

24 m

Alive/5

NA

H

MMAA gene p.T216P (c.646A>C)

Mutation
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Table 1. (Continued).
29

F

Yes

16 m

Alive/5

GR

H

MUT gene p.P615T
(c.1843C>A )

30

M

Yes

8m

Alive/4

GR

H

MMAA gene p.R196* (c.586C>T)

31

M

No

1m

Alive/5

NA

CH

MUT gene p.R108H (c.323G>A)/
IVS3+1G>T (c.752+1G>T)-novel

32

M

Yes

18 m

Alive/6

GR

H

MUT gene p.K121* (c.360_361insT)

33

M

Yes

2d

Alive/3

NA

H

MUT gene p.N219Y (c.655A>T)

34

M

Yes

2d

Alive/4

NA

H

MMAB gene p.R186Q (c.557G>A)

35

F

Yes

12 m

Alive/4

NA

H

MMAA gene p.H382Pfs*24
(c.1145delA) -novel

36

M

Yes

29 m

Alive/5

GR

H

MUT gene p.A137G (c.410C>G)

37

F

Yes

2d

Alive/1

DD

H

MUT genep.R474* (c.1420C>T)

GR: growth retardation; DD: developmental delay; RI: renal involvement; CMP: cardiomyopathy; LA: lactic acidosis; MMR: mental
motor retardation; HF: hepatic failure; NA: not available; m:months; d: days; H: homozygous; CH: compound heterozygous.

4. Discussion
This study expands the mutation spectrum for isolated
MMA in the Turkish population particularly highlighting the
extent of mutations in the south-eastern part of the country
with a large number of patients by using NGS. Moreover,
with the classification into the 3 complementation groups,
we can slightly anticipate the differences of the phenotypes
from the complementation groups and genotypes.
It is obvious to say that among all of the patients
presented in early childhood, almost one half of them had
their first symptoms in the neonatal period. All patients are
characterized by intermittent metabolic decompensation
periods triggered by infections, excessive protein intake,
and other stressors. MMA has some major complications
such as intellectual impairment, tubulointerstitial nephritis
with progressive renal failure, “metabolic stroke” (acute
and chronic basal ganglia injury) causing a disabling
movement disorder with choreoathetosis, dystonia, and
para/quadriparesis; pancreatitis, and growth failure [3].
The most common clinical complications of our patients
were growth retardation, renal involvement, mental motor
retardation, and developmental delay. Furthermore, one
of our patients developed cardiomyopathy, and another
one died because of hepatic failure. None of our patients
presented with pancreatitis. Moreover, patient 10 presented
with life-threatening lactic acidosis after 3 doses of
linezolid exposure. While linezolid is increasingly used as
a multidrug-resistant antibacterial agent, linezolid-induced
lactic acidosis has been frequently reported as a serious
side effect [23]. On the other hand, it is commonly believed
that MMA causes mitochondrial dysfunction by different
mechanisms. While elevated metabolites 2-methylcitrate,
methylmalonic acid (MA), and propionyl-CoA inhibit
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some mitochondrial enzymes, secondary respiratory chain
deficiency has also been identified in MMA patients [14].
2-methylcitrate inhibits citrate synthase, aconitase, and
isocitrate dehydrogenase, which are the key enzymes of
the tricarboxylic acid cycle (TCA); MA inhibits pyruvate
carboxylase, and propionyl-CoA inhibits CoA-dependent
enzymes pyruvate dehydrogenase, succinyl-CoA synthetase,
and ATP citrate lyase [20]. Thus, neurotoxic metabolites,
which inhibit the energy metabolism in various different
steps and respiratory chain deficiencies detected in many
tissues like liver, muscle, and proximale tubule cells may
enhance the formation of lactic acidosis induced by
linezolid.
The MUT gene mutations contribute to the majority
of the mutant alleles in the Turkish patients, similar to
the data from other populations [1,24,25]. We identified a
novel splicing mutation c. 752+1G>T (IVS3+1G>T) in one
patient in the compound heterozygote state. The second
allele was a missense mutation in exon 3;
c.323G>A (p.R108H) [26]. This patient was presented
with metabolic decompensation at the age of 1 month. He
is currently alive and 5 years old without any complications
under the treatment.
The frameshift mutation c.360_361insT (p.K121*) was
detected in four patients. This single nucleotide insertion
causes an immediate stop codon in exon 2. This mutation
was first described as a homozygous change in a mut 0
patient who had consanguineous parents [26]. Four of
our patients who have this change in a homozygous state
presented to the hospital before the age of 2. While three of
them are still alive with milder complications, one of them
died after developing severe neurological complications
and renal failure.
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Table 2. Identified mutations.
Gene/ Reference Seq

Protein Change

Nucleotid change

Exon

Mutation type

ACMG

MMAA/ NM_172250.2

p.H382Pfs*24

c.1145delA

7

Frame Shift

Pathogenic

MMAA/ NM_172250.2

p.G278D

c.833G>A

6

Missense

VUS

MMAA/ NM_172250.2

p.V220M

c.658G>A

4

Missense

Pathogenic

MMAA/ NM_172250.2

p.E773*

c.1117G>T

7

Nonsense

Pathogenic

MMAA/ NM_172250.2

p.R359Q

c.1076G>A

7

Missense

Pathogenic

MMAA/ NM_172250.2

p.R196*

c.586C>T

4

Nonsense

Pathogenic

MMAA/ NM_172250.2

p.R359*

c.1075C>T

7

Nonsense

Pathogenic

MMAA/ NM_172250.2

p.R330*

c.988C>T

7

Nonsense

Pathogenic

MMAA/ NM_172250.2

p.T216P

c.646A>C

4

Missense

VUS

MMAB/ NM_052845.3

p.R191W

c.571C>T

7

Missense

Pathogenic

MMAB/ NM_052845.3

p.R186Q

c.557G>A

7

Missense

VUS

MMAB/ NM_052845.3

p.E193K

c.577G>A

7

Missense

VUS

MUT/ NM_000255.3

p.R532H

c.1595G>A

9

Missense

Benign

MUT/ NM_000255.3

p.I671V

c.2011A>G

12

Missense

Benign

MUT/ NM_000255.3

p.T387I

c.1160C>T

6

Missense

VUS

MUT/ NM_000255.3

-

c.2055_2056insCTC

12

Deletion-inframe

Likely pathogenic

MUT/ NM_000255.3

p.R727*

c.2179C>T

13

Nonsense

Pathogenic

MUT/ NM_000255.3

p.M1T

c.2T>C

2

Missense

Likely pathogenic

MUT/ NM_000255.3

p.G454E

c.1361G>A

7

Missense

VUS

MUT/ NM_000255.3

p.N219Y

c.655A>T

3

Missense

Likely pathogenic

MUT/ NM_000255.3

p.K223R

c.668A>G

3

Missense

VUS

MUT/ NM_000255.3

p.R694W

c.2080C>T

12

Missense

Likely pathogenic

MUT/ NM_000255.3

p.A141Rfs*39

c.421delG

3

Frame Shift

Pathogenic

MUT/ NM_000255.3

p.K121*

c.360_361insT

2

Nonsense

Pathogenic

MUT/ NM_000255.3

p.P615T

c.1843C>A

11

Missense

Likely pathogenic

MUT/ NM_000255.3

p.R108H

c.323G>A

2

Missense

Pathogenic

MUT/ NM_000255.3

IVS3+1G>T

c.752+1 G>T

3+1

Splicing

Pathogenic

MUT/ NM_000255.3

p.347delL

(c.1038_1040delTCT)

3

Deletion

Likely pathogenic

MUT/ NM_000255.3

p.A137G

c.410C>G

3

Missense

Pathogenic

MUT/ NM_000255.3

p.R474*

c.1420C>T

7

Nonsense

Pathogenic

ACMG: American college of medical genetics; VUS: variant of uncertain significance.

A missense mutation of c.1160C>T (p.T387I) located
in exon 6 was found as a homozygous change in two
siblings; patient 4 and 5. Although the older one has renal
involvement, developmental delay, and mental retardation
as long-term complications, younger one has developed
none of these. This mutation has been firstly identified
in a 5-year-old Turkish patient who has only mental
retardation as a complication [15]. Another missense
mutation of c.1361G>A (p.G454E), which is located in
the linker region, has been found in two of our patients.
Both of them were presented at the third day of life. One
of them developed cardiomyopathy and linezolid-induced

lactic acidosis besides renal involvement. This missense
mutation has been found first in an Italian patient as
a heterozygous change with accompanying c.427C>T
(p.H143Y) mutation [27]. c.655A>T (p.219Y) mutation is
a common missense mutation reported in the Caucasian
population particularly in French and Turkish patients
[28]. We found this mutation in 3 patients; one of them
died because of hepatic failure.
From presumed missense mutations, we identified
two single nucleotide polymorphisms (SNP) p. R532H
and p.I69V in the MUT gene. Although these changes
have been determined as benign, which has not been
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accepted as a disease-causing variant, both patients had
significant clinical and laboratory features of MMA [26].
The functional analysis of this mutant allele bearing both
changes will provide insight about the real functional
consequences of these sequence variants. Also, while there
is no commercial multiplex ligation-dependent probe
amplification (MLPA) kit, we could not perform deletion
and duplication analysis in these cases. Further molecular
analysis should be performed in these patients.
c.2179C>T
(p.R727*),
c.2T>C
(p.M1T),
c.
2055_2056insCTC, c.668A>G (p.K223R), c.2080C>T
(p.R694W), c.421delG (p.A141Rfs*39), c.1843C>A
(p.P615T),
c.1038_1040delTCT (p.347delL), c.410C>G (p.A137G)
and c.1420C>T (p.R474*) are the other MUT mutations,
which have been previously reported [15, 26, 27, 29, 30] .
9 different MMAA gene mutations have been
described. While c.1145delA (p.H382Pfs*24) is a novel
frameshift mutation, other 8 mutations have been reported
previously. Four of them were missense mutations.
c.833G>A (p.G278D) was identified firstly in an Indian
infant who presented at 18 months-old with a typical
presentation including ketoacidosis and hyperammonemia
[31]. c.658G>A (p.V220M), c.1076G>A (p.R359Q) and
c.646A>C (p.T216P) are the other missense MMAA
gene mutations which were identified in our patients in a
homozygous state.
4 nonsense previously reported MMAA mutations
have been identified in our patients. c.586C>T (p.R196*)
mutation in exon 4 is a nonsense mutation predicted an
amino acid change from arginine to a premature stop
codon at position 196 in the mature protein. This nonsense
mutation has previously been reported in a compound
heterozygote patient with B12-responsive cblA-type
methylmalonic academia [32]. It has been also reported in

a homozygous state in a Turkish infant mimicking diabetic
ketoacidosis [33]. c.1075C>T (p.R359*) is another nonsense
mutation in exon 7, which has been previously identified
with a high-resolution melting analysis technique [34].
c.988C>T (p.R330*) is the other nonsense mutation at
codon 330. The mutation is 37 amino acids downstream of
a predicted GTP binding site [35]. c.1117G>T (p.E773*) is
the fourth nonsense mutation in exon 7, which was found
in our patients.
We have identified 3 missense mutations, which were
all previously reported as missense mutations: c.571C>T
(p.R191W), c.557G>A (p.R186Q) and c.577G>A (p.E193K)
in the MMAB gene [4, 36, 37].
In conclusion, we have detected two novel mutations,
including one splice-site mutation in the MUT gene and
one frame shift mutation in the MMAA gene in 37 Turkish
patients. In summary, we have reported the genetic basis
of three genes causing isolated MMA in Turkey providing
clinical data to explain the phenotypic differences of these
disorders.
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